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ORIGINAL RESEARCH

Variant R94C in TNNT2-Encoded Troponin T Predisposes to Pediatric
Restrictive Cardiomyopathy and Sudden Death Through Impaired Thin
Filament Relaxation Resulting in Myocardial Diastolic Dysfunction
Jordan E. Ezekian, MD, MPH;* Sarah R. Clippinger;* Jaquelin M. Garcia; Qixin Yang, MD; Susan Denﬁeld, MD;
Aamir Jeewa, MD; William J. Dreyer, MD; Wenxin Zou, PhD; Yuxin Fan, MD; Hugh D. Allen, MD; Jeffrey J. Kim, MD;
Michael J. Greenberg, PhD; Andrew P. Landstrom, MD, PhD

Background-—Pediatric-onset restrictive cardiomyopathy (RCM) is associated with high mortality, but underlying mechanisms of
disease are under investigated. RCM-associated diastolic dysfunction secondary to variants in TNNT2-encoded cardiac troponin T
(TNNT2) is poorly described.
Methods and Results-—Genetic analysis of a proband and kindred with RCM identiﬁed TNNT2-R94C, which cosegregated in a
family with 2 generations of RCM, ventricular arrhythmias, and sudden death. TNNT2-R94C was absent among large, populationbased cohorts Genome Aggregation Database (gnomAD) and predicted to be pathologic by in silico modeling. Biophysical
experiments using recombinant human TNNT2-R94C demonstrated impaired cardiac regulation at the molecular level attributed to
reduced calcium-dependent blocking of myosin’s interaction with the thin ﬁlament. Computational modeling predicted a shift in the
force-calcium curve for the R94C mutant toward submaximal calcium activation compared within the wild type, suggesting low
levels of muscle activation even at resting calcium concentrations and hypercontractility following activation by calcium.
Conclusions-—The pathogenic TNNT2-R94C variant activates thin-ﬁlament–mediated sarcomeric contraction at submaximal
calcium concentrations, likely resulting in increased muscle tension during diastole and hypercontractility during systole. This
describes the proximal biophysical mechanism for development of RCM in this family. ( J Am Heart Assoc. 2020;9:e015111. DOI:
10.1161/JAHA.119.015111.)
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estrictive cardiomyopathy (RCM) is a primary disorder of
increased myocardial stiffness and diastolic dysfunction
with often normal to slightly hypertrophied ventricular wall
thickness.1This disease typically manifests with marked atrial
dilation, attributable to transmission of elevated pressures
during ventricular relaxation, with preserved ventricular systolic function. The etiologies of RCM are broad, including
inherited and acquired causes, and the prognosis is poor.2,3

RCM comprises one of a group of primary muscle diseases of
the heart collectively called cardiomyopathies. Once thought
to be separate entities, cardiomyopathies are now thought to
be a spectrum of diseases with the presence of restrictive and
hypertrophic features varying across the phenotypes. Hypertrophic cardiomyopathy (HCM) is common and is associated
with mutations in sarcomere protein-encoding genes.4–7 RCM
and HCM patients often share the feature of diastolic
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What Is New?
• TNNT2-encoded cardiac troponin T TNNT2-R94C is a heritable
cause of restrictive cardiomyopathy and sudden death.
• This pathologic variant leads to initiation of cardiac muscle
contraction at resting calcium levels.
• Computational modeling predicts that this causes increased
basal muscle tension and likely leads to diastolic cardiac
dysfunction.

presentations, including arrhythmias, cardiomyopathy with
predominantly restrictive physiology, and sudden death. We
used biochemical techniques and computational modeling to
demonstrate that this variant is likely pathogenic, and we
determined its molecular mechanism. We show that this
variant causes activation of the thin ﬁlament at submaximal
calcium concentrations, contributing to diastolic dysfunction
as observed in this family.

Methods
What Are the Clinical Implications?
• Pediatric restrictive cardiomyopathy is a rare cause of
sudden cardiac death in children.
• This study demonstrates the pathological mechanism of the
TNNT2-R94C variant.
• Patients with this variant should be followed closely for
development of cardiomyopathy and/or arrhythmias, and
familial screening should be performed when the variant is
discovered in an individual.
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dysfunction, and a subset of patients with RCM demonstrate
mild ventricular hypertrophy. The genetic mechanisms underlying RCM, corresponding clinical phenotypes, and subclass of
RCM with hypertrophic features have not been well described.
To date, >1000 variants associated with cardiomyopathy
have been identiﬁed in sarcomeric genes, including TNNT2encoded cardiac troponin T (TNNT2).7,8 TNNT2 combines with
the calcium-binding proteins troponin C and troponin I to form
the troponin complex. This troponin complex is integrated
into the thin ﬁlament of the sarcomere and, in combination
with tropomyosin, coordinates contraction of the cardiac
muscle by regulating the calcium-dependent interaction
between myosin and the thin ﬁlament. TNNT2-speciﬁc gene
variants are a known, rare cause of HCM, found in 3% to 5% of
patients with HCM.9 They have also been associated with the
development of ventricular arrhythmias.10–13 Recent studies
have suggested that variants in TNNT2 may also be associated with development of RCM.14–16 For example, the TNNT2
variant, I79N, has been shown to cause RCM and HCM within
the same family.17 Previous biochemical studies have suggested that TNNT2 variants identiﬁed in patients with HCM
and dilated cardiomyopathy result in alterations in calcium
sensitivity, leading to systolic dysfunction.18,19 Based on
these ﬁndings, this molecular mechanism has been extrapolated to disorders of diastolic dysfunction. To conﬁrm this
hypothesis, variants known to produce a clinical phenotype of
primary diastolic dysfunction and RCM should be studied to
conﬁrm the underlying molecular mechanisms.
Herein, we identify a TNNT2 variant, TNNT2-R94C, in a
family with multiple members affected with a range of clinical
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The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.

Clinical Evaluation
This study received approval from the institutional review
boards at Baylor College of Medicine and Duke University
Health System. Available clinical data from the identiﬁed
proband and relatives were collected, which included pertinent personal and family history, physical examination,
standard 12-lead ECG analysis, echocardiographic testing,
cardiac catheterization data, and genetic testing. An autopsy
was performed on the brother of the proband by the Medical
Examiner Service of the Harris County, Texas, Institute of
Forensic Sciences (Houston, TX) following his death. The
family underwent a full evaluation by pediatric cardiomyopathy and heart failure specialists.

Genetic Analysis
The proband underwent clinical genetic testing using the
Famillion (New Haven, CT) HCM panel test, which involves
sequencing 9 sarcomeric genes (ACTC, MYBPC3, MYH7, MYL2,
MYL3, TNNT2, TNNI3, TNNC1, and TPM1) and 3 metabolic
genes (GLA, LAMP2, and PRKAG2). Clinical genetic testing was
performed on family members using the same HCM panel test.
Subsequently, Sanger sequencing was utilized for conﬁrmatory
testing. For this, genomic DNA was isolated using the Gentra
Puregene Blood Kit (Qiagen, Valencia, CA) from peripheral
whole blood as well as postmortem blood spot. To conﬁrm the
absence of the identiﬁed presumed pathogenic variant in
ostensibly healthy individuals, the publicly available Genome
Aggregation Database (gnomAD) was used as a control cohort,
which is comprised of a total of 15 708 genomes and 125 748
exomes from 141 456 individuals.20 Though the gnomAD
database is comprised partly of various disease-speciﬁc
cohorts in addition to population genetics studies, it excludes
individuals known to have severe pediatric disease or severe
disease in their ﬁrst-degree relatives. These individuals were
therefore utilized as “control” or “reference” alleles. Variant
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Sequencing Conservation
Sequence conservation analysis was performed using the
primary TNNT2 sequence obtained from the National Center
for Biotechnology Information (NP_001001430.1).23 Multalign alignment algorithms were utilized to determine sequence
conservation across species.24,25

In Silico Variant Pathogenicity Modeling
In silico variant pathogenicity prediction was performed using
GenMAPP,26 PolyPhen-2,27 PredictSNP,28 SIFT,29 SNAP,30 and
PANTHER31 prediction tools. Variants were considered
pathogenic if they carried the designation of “damaging or
probably damaging,” “deleterious,” “disease-related,” and/or
“disease-associated.” Variants were considered benign if they
carried designation of “tolerated,” “benign,” or “neutral.”

Puriﬁcation of Cardiac Myosin and Actin

Downloaded from http://ahajournals.org by on April 3, 2020

Porcine cardiac ventricular myosin and actin were puriﬁed
from cryoground tissue as previously described.32–34 Myosin
subfragment 1 was prepared by chymotrypsic digestion as
previously described,32 using standard techniques,35,36 and
the purity of the protein was assessed by SDS-PAGE. The
concentration of myosin subfragment 1 was determined by
absorbance at 280 and 320 nm. Pyrene-labeled actin was
prepared from acetone powder37 and labeled with the dye,
N-(1-pyrenyl)iodoacetamide (pyrene), as described previously.38,39 Concentration of pyrene actin was determined by
absorbance at 290 and 344 nm. Before use, all actin was
stabilized by incubating with equimolar concentrations of
phalloidin.

Preparation of Recombinant Human Troponin and
Tropomyosin
Human cardiac tropomyosin was expressed in BL21-CodonPlus cells (Agilent Technologies, Santa Clara, CA) and puriﬁed
using established protocols.32,33,40,41 On the day of the
experiment, tropomyosin was reduced in 50 mmol/L of DTT
at 56°C for 5 minutes, and aggregates were subsequently
removed by ultracentrifugation at 436 000g in an Optima
MAX-TL Ultracentrifuge (Beckman Coulter, Brea, CA).42 The
R94C variant was introduced into TNNT2 using the QuickChange Site-Directed Mutagenesis kit (Agilent Technologies).
Human troponins I, T, and C were expressed in BL21DOI: 10.1161/JAHA.119.015111

CodonPlus cells (Agilent Technologies), puriﬁed, and complexed using established protocols.43

Determination of KB Using Stopped Flow
Transient Kinetics
To determine the equilibrium constant between the blocked
and closed states, KB, a stopped ﬂow approach developed by
McKillop and Geeves32,44 was utilized. This method analyzes
the rate of myosin binding to reconstituted thin ﬁlaments in
the presence and absence of calcium. Pyrene-actin was
excited at 365 nm, and ﬂuorescence emission was detected
using a 390 nm long-pass ﬁlter. Reconstituted thin ﬁlaments
(5 lmol/L of phalloidin-stabilized pyrene actin, 2 lmol/L of
tropomyosin, and 2 lmol/L of troponin) and 0.04 U/mL of
apyrase were rapidly mixed with 0.5 lmol/L of subfragment
1 myosin and 0.04 U/mL of apyrase at 20°C in an SX-20
stopped ﬂow apparatus (Applied Photophysics, Leatherhead,
UK). The high calcium (pCa 4) buffer contained 200 mmol/L
of KCl, 5 mmol/L of MgCl2, 60 mmol/L of MOPS, 2 mmol/L
of EGTA, 1 mmol/L of DTT, and 2.15 mmol/L of CaCl2. The
low calcium (pCa 9) buffer contained 200 mmol/L of KCl,
5 mmol/L of MgCl2, 60 mmol/L of MOPS, 2 mmol/L of
EGTA, 1 mmol/L of DTT, and 5.2 lmol/L of CaCl2. Myosin
strong binding to pyrene-labeled actin in reconstituted thin
ﬁlaments quenches pyrene ﬂuorescence. Fluorescence transients were collected for at least 3 separate mixes, and a
single exponential function was ﬁt to the transient. KB is
calculated from the ratio of the rates of myosin binding to the
reconstituted thin ﬁlaments at high and low calcium44:
kobs ðCa2þ Þ
KB

2þ
kobs ðþCa Þ 1 þ KB

(1)

The average KB was calculated from 3 different experiments, and the P value was calculated from a 2-tailed Student
t test.

Determination of KW, KT, and n From
Fluorescence Titrations
Values of the equilibrium constant between the open and
weakly bound myosin states, KW, the equilibrium constant
between the closed and open states KT, and the size of the
cooperative unit (ie, the number of binding sites on the thin
ﬁlament opened by myosin binding), n, were determined by
measuring the steady-state binding of myosin to pyrene-labeled
regulated thin ﬁlaments.44 Fluorescence titrations were carried
out at 20°C in an Applied Photophysics SX-20. Myosin S1 was
added at 1-minute intervals to a stirred cuvette containing
0.5 lmol/L of pyrene-actin, 0.27 lmol/L of troponin, and
tropomyosin up to a ﬁnal concentration of 10 lmol/L of
Journal of the American Heart Association
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pathogenicity classiﬁcation was also assigned based on 2015
American College of Medical Genetics criteria21 and ClinVar
(National Center for Biotechnology Information).22
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a¼

F0  F
KW ½M P n1 ðKT ð1 þ KS Þn þ1Þ

¼
F0  F1
KT P n þ Qn þ K1B ð1 þ KS Þn1

(2)
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where F is the measured ﬂuorescence, F0 is the ﬂuorescence
of the pyrene in the absence of myosin binding, F∞ is the
ﬂuorescence at saturating myosin concentrations, n is the
size of the cooperative unit, P=1+KW[M](1+KS), and
Q=1+KW[M].44 For the ﬁtting, the equilibrium constant
between the closed and open states (KT), the equilibrium
constant between the open and myosin weakly bound state
(KW), and n were ﬁtted parameters. Titration curves were
globally ﬁt to extract parameter values, 95% CIs by bootstrapping simulations, and P values were determined as
described.32 KB was ﬁxed based on stopped ﬂow experiments.
The equilibrium constant between the states in which myosin
is weakly and strongly bound to the thin ﬁlament (KS) was
ﬁxed based on previous studies.45

Computational Modeling of the Variants on Thin
Filament Regulation
To quantitatively model the impacts of the variant on overall
calcium-force production relationship in the heart, we utilized
a computational model developed by the McCulloch laboratory, which uses the measured equilibrium constants to
calculate the expected force per sarcomere as a function of
calcium.46 Model parameters for the mutant protein were
adjusted to be proportional to our measured parameters, and
we used these parameters to simulate a force-calcium curve.
For the WT protein, we used the default model parameters.

Statistical Analysis
A Student t test was performed to determine statistical
signiﬁcance between 2 groups. P<0.05 was considered
signiﬁcant, unless otherwise noted.

DOI: 10.1161/JAHA.119.015111

Results
Clinical Evaluation
The proband is a 2-year-old white girl who was found to have
RCM following an evaluation precipitated by the sudden death
of her older brother. Her ECG demonstrated criteria for right
and left atrial enlargement with marked repolarization abnormality. Echocardiogram revealed mild right atrial and severe
left atrial enlargement (left atrial volume, 61.5 cc/m2; normal,
16–28), with mildly increased left ventricular mass and
otherwise normal ventricular dimensions. Right and left
ventricular systolic function was preserved. These ﬁndings
were consistent with a mild form of HCM with markedly
restrictive physiology (Figure 1A and 1B). The proband
suffered a cardiac arrest during phlebotomy and was unable
to be resuscitated.
Her seemingly healthy 4-year-old brother presented with a
sudden cardiac arrest while running on a soccer ﬁeld and could
not be resuscitated. Autopsy revealed mild cardiomegaly (heart
weighed 147 g; normal, 55–121) with mild biventricular
hypertrophy (left ventricular free wall 0.8 cm (echocardiographic Z-Score, +3.53), interventricular septum 0.9 cm
(echocardiographic Z-Score, +4.78), and right ventricular free
wall (0.3 cm) with myocyte hypertrophy and disarray found on
histopathological examination.47,48 These ﬁndings were determined to be consistent with a diagnosis of HCM, which was
identiﬁed as the cause of death. Signiﬁcant left ventricular
outﬂow tract obstruction was not present. No genetic testing
was performed at the time of death. Because of this diagnosis,
clinical evaluation of the family was conducted, which included
phenotypic screening and genetic testing.
The proband’s father is a 35-year-old male who was found
to have episodes of asymptomatic, nonsustained ventricular
tachycardia and premature ventricular beats on event monitoring in the setting of normal biventricular size and systolic
function. Cardiac magnetic resonance imaging demonstrated
normal myocardium and marked right and left atrial enlargement, consistent with diastolic dysfunction and RCM (Figure, 1C through 1E).

Genetic Evaluation
Cardiomyopathy-based panel testing (Familion; Transgenomic,
Inc., New Haven, CT) was conducted on the proband,
demonstrating a single, heterozygous, variant TNNT2-R94C
(c.280C>T). No other variants were identiﬁed in other
cardiomyopathy-associated genes. This variant was absent
in gnomAD and localized to a highly conserved portion of the
N-terminal domain near the tropomyosin binding site (Figure 2A and 2B). To test whether this variant was found among
all affected individuals, family history was expanded, and a
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subfragment 1. Buffers contained 200 mmol/L of KCl,
5 mmol/L of free MgCl2, 60 mmol/L of MOPS, 2 mmol/L of
EGTA, 1 mmol/L of DTT, and 2 mmol/L of ADP and the desired
free concentration of free calcium. Any contaminating ATP was
eliminated by adding 50 lmol/L of P1,P5-di(adenosine-50 )
pentaphosphate, 2 mmol/L of glucose, and 1 lmol/L of
hexokinase. Titrations were performed at 3 calcium concentrations: low (2 mmol/L of EGTA), intermediate (pCa 6.25), and
high (pCa 3). Five technical replicates were performed. Data
was analyzed as previously described.32
To quantify differences in myosin binding of the wild-type
(WT) and mutant proteins, titration curves were ﬁt to the
fractional change in the ﬂuorescence, a, as a function of
myosin, [M], given by:
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D

E

Figure 1. Clinical evaluation of TNNT2-R94C–positive kindred. (A) Representative ECG obtained from the proband demonstrating right and left
atrial enlargement with nonspeciﬁc ST and T-wave abnormalities and ST depression in the inferolateral leads. An enlarged representative ECG is
shown. (B) Representative echocardiographic images in the parasternal long axis and apical 4-chamber windows demonstrating severe left atrial
enlargement. (C) Cardiac telemetry demonstrating ventricular tachycardia overtaking sinus rhythm. (D) Representative echocardiographic
images from the father of the proband in the parasternal short-axis view demonstrating normal LV size and systolic function. (E) Representative
cardiac MRI images demonstrating right and left atrial enlargement with normal biventricular size and function. LV indicates left ventricular; MRI,
magnetic resonance imaging; TNNT2, TNNT2-encoded cardiac troponin T.
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total of 8 kindred were consented and subjected for
conﬁrmatory genetic testing. In addition to the proband
(IV.3), postmortem genetic testing of the deceased brother
(IV.2) also demonstrated presence of the heterozygous
TNNT2-R94C variant. While a ﬁrst trimester fetal death
(IV.4) was also identiﬁed from the mother (III.4), no fetal
tissue was available for genetic analysis. The father (III.3) was
also found to carry the TNNT2-R94C, which was absent in
both paternal grandparents (II.1 and II.2) and paternal sibling
(III.2), suggesting a de novo variant that was subsequently
passed in an autosomal-dominant fashion. This is summarized
in Figure 3. In silico prediction modeling was performed and
demonstrated a prediction of deleterious impact from 5 of 6
models and neutral from 1 model, with an average conﬁdence
of 74.6% (Tabl). This variant was designated as pathologic in
ClinVar, and there is strong evidence of pathogenicity based
on 2015 American College of Medical Genetics criteria21 for
classifying pathogenic variants.

R94C Destabilizes the Blocked State of
Tropomyosin and Increases the Equilibrium
Constant for Myosin Weak Binding to the Thin
Filament
Cardiac troponin T is part of the machinery that regulates the
calcium-dependent interactions between myosin and the thin
DOI: 10.1161/JAHA.119.015111

ﬁlament (Figure 4A). To determine the molecular consequences of the TNNT2-R94C variant on cardiac contractile
regulation, we expressed human WT (TNNT2WT) and mutant
troponin (TNNT2R94C) and determined the biochemical
impacts on thin ﬁlament regulation.
The ﬁrst step in muscle activation is the calcium-induced
change in positioning of tropomyosin along the thin ﬁlament,
moving it from the blocked to the closed state. The
equilibrium constant that deﬁnes this transition, KB, was
calculated by measuring the rate of myosin binding to
reconstituted thin ﬁlaments containing pyrene-labeled actin
at high- and low-calcium concentrations.32,44 The pyrene
ﬂuorescence is quenched upon myosin binding, and the rate
of myosin binding to the thin ﬁlament can be calculated by
ﬁtting an exponential function to the ﬂuorescence transient
(Figure 4B). In TNNT2WT, the rate of binding at high calcium
(pCa 4) is faster than at low calcium (pCa 9) given that the
blocked state is scarcely populated at high calcium. Whereas
the ﬂuorescence transients collected at high calcium are
similar for the TNNT2WT and TNNT2R94C, at low calcium,
TNNT2R94C binds faster than the TNNT2WT, consistent with
less inhibition at low calcium in TNNT2R49C. Consistent with
this notion, we found that KB for TNNT2R94C (0.670.17) is
signiﬁcantly larger than KB for the WT (0.400.15; P=0.04).
This result demonstrates that the inhibitory blocked state is
less populated in TNNT2R94C at low calcium compared with
Journal of the American Heart Association
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Figure 2. R94C localizes to a highly conserved region of TNNT2. (A) Sanger sequencing chromatograms of heterozygous mutant TNNT2-R94C
(obtained from subject III-3) and wild-type genotypes. (B) The topological map of TNNT2 with primary sequence alignment from multiple
divergent species is shown. The variant localizes to the N-terminal segment of TNNT2 in the tropomyosin binding domain I. This region is highly
conserved across species. AH indicates actin helix; BD, binding domain; TnC, troponin C; TnI, troponin I; TNNT2, TNNT2-encoded cardiac
troponin T; WT, wild type.

the TNNT2WT. This loss of inhibition at low calcium would lead
to hypercontractility (ie, increased population of forcegenerating states) and create a predisposition toward
myocardial stiffness and ultimately diastolic dysfunction.
Next, we examined the effects of TNNT2R94C on the closed,
open, and myosin-bound states of the thin ﬁlament (Figure 4A) by performing steady-state titrations of myosin
binding to reconstituted pyrene-labeled thin ﬁlaments at high
(pCa 3), low (2 mmol/L of EGTA), and intermediate calcium
concentrations (pCa 6.25)32,44 (Figure 4C and 4D). Qualitatively, the myosin binding isotherms for the TNNT2WT and
TNNT2R94C thin ﬁlaments are similar at high and intermediate
calcium concentrations; however, at low calcium, myosin
binding to TNNT2R94C thin ﬁlaments is increased at low
myosin concentrations compared with TNNT2WT. These
ﬁndings are consistent with the stopped ﬂow data showing

DOI: 10.1161/JAHA.119.015111

less inhibition to myosin binding at low calcium. Fitting of the
data (see Table S1 for details) demonstrates that TNNT2R94C
has an increased equilibrium constant for myosin weak
binding, KW (0.20 0.03/+0.16 for TNNT2R94C versus 0.13
0.01/+0.01 for the WT; P=0.002). The variant does not
signiﬁcantly change the equilibrium constant between the
closed and open states. This includes KT, (0.11 [0.08, 0.12]
for TNNT2R94C versus 0.06 [0.03, 0.06] for the WT at low
calcium, P=0.43; 0.07 [0.04, 0.05] for TNNT2R94C versus
0.08 [0.04, 0.04] for the WT at intermediate calcium,
P=0.45; and 0.14 [0.08, 0.09] for TNNT2R94C versus 0.18
[0.07, 0.08] for the WT at high calcium, P=0.37). Furthermore, cooperativity of activation was unchanged between
TNNT2R94C versus TNNT2WT, n (4.47 [1.66, 2.18] for
TNNT2R94C versus TNNT2WT; P=0.18). These results are
summarized in Figure 5A and 5B.
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Figure 3. Pedigree of TNNT-R94C kindred. Four generations were evaluated (denoted by roman numerals). Clinical presentations are noted in red.
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The predominant phenotype is an RCM with mild hypertrophic features. Arrow denotes the proband (IV.4). Circles denote female, and squares
denote male. Black ﬁll denotes diagnosis of cardiomyopathy. Gray ﬁll denotes fetal demise (IUFD). White ﬁll denotes no cardiac diagnosis either
following clinical evaluation or by reported history. +/ denotes heterozygosity for TNNT2-R94C variant whereas / denotes wild type. Diagonal
line denotes deceased. HCM indicates hypertrophic cardiomyopathy; IUFD, intrauterine fetal demise; LVH, left ventricular hypertrophy; RCM,
restrictive cardiomyopathy; SCD, sudden cardiac death; TNNT2, TNNT2-encoded cardiac troponin T; VT, ventricular tachycardia.

Computational Modeling Reveals
Hypercontractility in TNNT2R94C
These biochemical experiments identiﬁed the primary effects
of TNNT2R94C on thin ﬁlament regulation as 2-fold increases in
the values for both KB and KW. Computational modeling was

Table. In Silico Variant Prediction Aggregate Analysis of the
TNNT2 Arg94Cys Variant Using Variant Prediction Models

Tool

Algorithm

Clinical
Signiﬁcance

Conﬁdence
(%)

GenMAPP

Pathway analysis tool

Deleterious

72

PolyPhen-2

Na€ıve Bayes classification

Deleterious

81

PredictSNP

Metaserver

Deleterious

76

SIFT

Sequence conservation

Deleterious

79

SNAP

Neural networks

Neutral

50

PANTHER

Ontology association

Deleterious

65

GenMAPP indicates gene map annotator and pathway proﬁler; PANTHER, protein
analysis through evolutionary relationships; PolyPhen-2, polymorphism phenotyping v2;
SIFT, sorting intolerant from tolerant.
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used to predict how these changes in equilibrium constants
would affect the force-calcium curve in cardiac muscle.46
Modeling demonstrates a shift in the force-pCa curve for
TNNT2R94C toward submaximal calcium activation compared
with TNNT2WT, consistent with molecular hypercontractility.
The model also predicts that even at resting calcium
concentrations (100–150 nmol/L49,50), there could be some
basal level of activation with TNNT2R94C (Figure 5C). Taken
together, these data demonstrate that TNNT2R94C would yield
less calcium-induced inhibition to contraction, leading to
hypercontractility and potentially an increase in basal muscle
tension. These contractile defects could lead to diastolic
dysfunction, culminating in restrictive cardiac physiology.

Discussion
Spectrum of Cardiomyopathy Phenotypic
Presentation
Recent advances in high-throughput sequencing have facilitated the identiﬁcation of a number of novel cardiomyopathyJournal of the American Heart Association
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Figure 4. Measurement of the biochemical steps involved in thin ﬁlament activation. (A) Kinetic scheme for thin ﬁlament activation.
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Tropomyosin lies along the thin ﬁlament in 3 positions: blocked (red), closed (yellow), and open (green). Positioning of tropomyosin depends
both on calcium and myosin binding. Myosin binds weakly to the thin ﬁlament before undergoing an isomerization to the strong-binding state,
where force is generated. (B) Measurement of KB, the equilibrium constant between the blocked and closed states, was measured by rapidly
mixing myosin with pyrene-labeled thin ﬁlaments at low (pCa 9) and high calcium (pCa 4). Myosin binding quenches ﬂuorescence. The ratio of
the rates of binding at high and low calcium can be used to calculate KB (see Methods). There is signiﬁcantly less blocking in the R94C mutant
than the WT at low calcium, as evidenced by the faster binding of the mutant at low calcium. (C and D) Equilibrium titrations of myosin with
pyrene-labeled regulated thin ﬁlaments enable the calculation of several equilibrium constants (see Methods). Experiments were conducted with
thin ﬁlaments containing either (C) TNNT2WT or (D) TNNT2R94C. TNNT2 indicates TNNT2-encoded cardiac troponin T.

associated genes, with the number identiﬁed as pathogenic
increasing signiﬁcantly over the last few years.9 Because of
the increased utilization of this technology, it is now possible
to identify shared genetic variants among phenotypically
dissimilar individuals, whose clinical presentations have not
previously been associated with speciﬁc genes.51 This has
increased understanding of the role of genetic variants in the
predisposing pathophysiological mechanisms of atypical
forms of cardiomyopathy.52 Here, we describe a variant
associated with relatively mild hypertrophy and clear evidence
of restrictive physiology consistent with RCM. It is well
established that cardiomyopathic diseases, including RCM,
have variable expressivity of disease frequently yielding a wide
spectrum of phenotypes.53,54 This study is supportive of these
previous ﬁndings.
We report on a family in which a single variant in TNNT2 is
associated with restrictive cardiomyopathy and sudden cardiac
death. The TNNT2-R94C variant was not observed in control
populations and was predicted to be deleterious by in silico
modeling, ClinVar, and current American College of Medical
Genetics guidelines. Our biochemical data show a clear
molecular phenotype that would be consistent with hypercontractility and diastolic dysfunction, supporting the concept that
DOI: 10.1161/JAHA.119.015111

this variant is causative for the disease. There are a total of 5
previous reports of the TNNT2-R94C variant (National Center
for Biotechnology Information ClinVar database), all with the
designation of “pathogenic” or “likely pathogenic” and associated with familial HCM.13,55–58 There has only been 1 previous
report of a TNNT2 variant causing restrictive physiology by
autosomal-dominant inheritance.13 Although the TNNT2-R94C
variant has been previously associated with HCM, the spectrum
of phenotypic features associated with TNNT2-R94C, including
RCM, has not been well described.

Contractile Defects Caused by the R94C Variant
Overall, the clinical phenotype of RCM consists of severe
diastolic dysfunction leading to atrial enlargement and, at
most, mild ventricular hypertrophy. The molecular mechanisms of contractile defects causing diastolic disease remain
largely unknown. Reﬂecting this, genetic causes of pediatric
RCM cases remain unexplained, with only rare patients
hosting variants within the thin ﬁlament. Here, we put forward
TNNT2-R94C as a likely causative of disease. TNNT2 is part of
the troponin complex that regulates calcium-dependent
interactions between the molecular motor myosin and thin
Journal of the American Heart Association
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Figure 5. (A) Simpliﬁed kinetic scheme for thin ﬁlament activation. (B) Equilibrium constants measured for the thin ﬁlaments containing

TNNT2WT and TNNT2R94C. The mutant causes statistically signiﬁcant increases in KB and KW. (C) Computational modeling of the effects of the
variant on the force-calcium relationship. The variant causes a leftward shift in the curve, signifying hypercontractility at lower calcium and a
basal level of tension, even at resting calcium concentrations. KB indicates the equilibrium constant between the blocked and closed states; KW,
the equilibrium constant between the closed and open states; TNNT2, TNNT2-encoded cardiac troponin T; WT, wild type.
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ﬁlament. R94 is located in the highly conserved region of the
TNNT2 N-terminal segment, and it is located near other
residues that have been associated with other forms of
cardiomyopathy, such as R92.59–64 Currently, there is no highresolution molecular structure of the thin ﬁlament or this
region of TNNT2, so it is not possible to determine the exact
structural basis of the biophysical changes that we observe;
however, it has been proposed that this region plays an
important role in mediating interaction between tropomyosin
and the troponin complex. HCM variants in this region have
been associated with reduced afﬁnity of troponin for
tropomyosin,65,66 leading to the proposal that variant-induced
changes in this afﬁnity could reduce the ability of troponin to
regulate interactions between myosin and the thin ﬁlament.65
Our data, showing destabilization of the blocked state, would
be consistent with this concept.
Previous analyses of the biochemical effects of HCMassociated TNNT2 mutations at the R94 position have
demonstrated that appropriate calcium regulation is critical
to normal function of the troponin complex.18,19 Based on
these ﬁndings, calcium sensitization is hypothesized to have a
direct impact on cardiac systolic function, with calcium
desensitization likely leading to decreased systolic function
and calcium sensitization likely leading to increased systolic
function. The described R94C variant is novel in that it
produces a clinical phenotype of RCM and primarily diastolic
dysfunction, making it an optimal variant for biochemical
studies to investigate the interaction between calcium
sensitivity and diastolic dysfunction.
Our computational modeling predicts that the R94C variant
will lead to submaximal calcium activation and possibly an
DOI: 10.1161/JAHA.119.015111

increase in basal tension during diastole. Previous studies of
many HCM variants have demonstrated similar shifts toward
submaximal calcium activation, leading to the proposal that
these variants cause net hypercontractility and diastolic
dysfunction. The phenotype observed in R94C patients,
consisting of a primarily restrictive phenotype with mild
hypertrophy, would be consistent with this hypothesis.

Limitations
Although we illustrate a novel genetic cause of RCM, our
ﬁndings are based around a single family and may limit study
generalizability. Our classiﬁcation of this variant as causative
for the disease is supported by our biochemical studies
demonstrating that the introduction of this single point variant
alone causes hypercontractility and features of diastolic
dysfunction at the molecular scale. Further studies are
warranted to determine how the ﬁndings presented here
translate to cellular and organ levels; however, our study
clearly identiﬁes the initial lesion that leads to downstream
changes with disease progression. Clinical genetic testing for
patients with cardiomyopathic disease is routinely limited to
genes of the sarcomere and metabolism, which are known
causes of cardiomyopathy. It is possible that another variant
or variants may be contributing to the severe phenotype
observed in the family. This is unlikely, considering that the
results of our biochemical experiments clearly demonstrate a
pathological mechanism of disease.
Moreover, caution should be used when extrapolating the
results here to the disease progression observed in human
patients. Our biochemical experiments and modeling were
Journal of the American Heart Association
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Conclusions
The R94C variant in TNNT2 is a novel genetic cause of RCM
occurring in a conserved domain which causes dysfunction of
calcium-based regulation of cardiac contraction and likely
yields signiﬁcant myocardial diastolic dysfunction. This variant,
when compared with control cohorts, has a high likelihood of
producing a malignant phenotype. Furthermore, this work
demonstrates the power of using in vitro biochemical studies as
well as computational modeling to support disease causality.
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Table S1. Clinical and genetic information for the multi-generational family.
Individual

Sex

Status

I.1
I.2
I.3
I.4
II.1
II.2
II.3
II.4
III.1
III.2
III.3
III.4
IV.1
IV.2

Age
(years)
78
83
81
83
59
60
57
Unknown
33
31
35
36
4
4

M
F
M
F
M
F
M
F
M
F
M
F
M
M

Deceased
Deceased
Deceased
Alive
Alive
Alive
Deceased
Alive
Alive
Alive
Alive
Alive
Alive
Deceased

TNNT2-R94C
Status
Unknown
Unknown
Unknown
Unknown
-/-/Unknown
Unknown
Unknown
-/+/-/-/+/-

IV.3

2

F

Deceased

+/-

IV.4

Fetus

Unknown

Deceased

Unknown

Cardiovascular Phenotype

Atrial fibrillation

Supraventricular tachycardia
Ventricular tachycardia

Hypertrophic cardiomyopathy with
restrictive features, sudden cardiac
arrest
Restrictive cardiomyopathy with mild
hypertrophy, sudden cardiac arrest
First trimester fetal death

Downloaded from http://ahajournals.org by on April 3, 2020

